China Feihe Ltd stock (KYG2108Y1052): earnings rebound and dividend highlight infant formula focus

China Feihe Ltd recently reported full-year 2024 results and proposed a final dividend, keeping its infant formula franchise in focus for investors watching Chinese consumer names.

China Feihe Ltd, a major Chinese infant formula producer listed in Hong Kong, has drawn investor attention after releasing its full-year 2024 results and proposing a final dividend, according to a company announcement dated 03/27/2025 on the Hong Kong Stock Exchange and the firm’s investor relations siteHKEX filing as of 03/27/2025China Feihe IR as of 03/27/2025.

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: China Feihe
• Sector/industry: Consumer staples, dairy and infant nutrition
• Headquarters/country: Beijing, China
• Core markets: Mainland China infant and adult nutrition products
• Key revenue drivers: Branded infant milk formula and related dairy products
• Home exchange/listing venue: Hong Kong Stock Exchange (ticker: 6186.HK)
• Trading currency: Hong Kong dollar (HKD)

China Feihe Ltd: core business model

China Feihe focuses on producing and marketing infant milk formula, adult milk powder and other dairy products primarily for Chinese consumers. The company positions itself in the premium and ultra-premium infant formula segments, an area where brand trust and distribution reach are critical. Its portfolio includes products designed for different age groups and nutritional needs.

The group’s historical strategy has centered on deep penetration into lower-tier Chinese cities combined with targeted marketing in higher-tier urban centers. This approach aims to capture both mass-market and higher-income households seeking premium nutrition products for infants and toddlers, according to company presentations published alongside earlier annual reportsChina Feihe IR as of 03/28/2024.

In addition to branded formula, China Feihe has broadened its offerings to related dairy categories such as adult milk powder and other nutritional products. While infant formula remains the dominant revenue contributor, diversification into adjacent categories provides additional scale benefits in sourcing, production and distribution.

Main revenue and product drivers for China Feihe Ltd

Infant milk formula makes up the bulk of China Feihe’s revenue and profits. Within this category, premium and ultra-premium brands typically carry higher margins than standard offerings. These lines benefit from brand strength, marketing investment and perceived quality differences, according to the company’s description of its product mix in its 2023 annual report released in March 2024HKEX report as of 03/28/2024.

China’s demographic backdrop, including declining birth rates, has made competition more intense among formula producers. China Feihe has responded by emphasizing product innovation, expanding online sales channels and maintaining a large network of offline distributors. The company highlights its research and development around nutrition and formula composition as a differentiator within the market.

Beyond core infant formula, adult and elderly nutrition products contribute an additional revenue stream. These categories may benefit from China’s aging population, creating a separate demand driver compared with infant-related products. The company also participates in other dairy-related categories that leverage its existing manufacturing and procurement infrastructure.

Recent financial performance and dividend move

For the year ended 12/31/2024, China Feihe reported revenue and profit figures that reflected the competitive environment and evolving consumer demand in China’s infant formula sector. The company disclosed its 2024 results on 03/27/2025, detailing performance in core product lines and profitability trendsChina Feihe IR as of 03/27/2025.

In the same announcement, the board proposed a final dividend for the 2024 financial year, subject to shareholder approval at the annual general meeting. The proposed payout underscores management’s focus on returning cash to shareholders while continuing to fund operations and potential growth initiativesHKEX filing as of 03/27/2025.

Previous years’ disclosures showed that China Feihe had maintained regular dividend distributions, aligning with the company’s cash-generating profile from its established brands. The continuation of a dividend proposal for 2024 indicates ongoing confidence in the business’s ability to support shareholder returns, although the exact amount and yield depend on the company’s share price and final approval.

Why China Feihe Ltd matters for US investors

Although China Feihe is listed in Hong Kong rather than on a US exchange, the stock may still be relevant to US investors accessing international markets through global brokerages. The company offers exposure to Chinese consumer spending, particularly in the infant and nutrition categories, which can behave differently from discretionary segments during economic cyclesHKEX data as of 04/02/2025.

For US-based portfolios, China Feihe represents a specialized play on the Chinese dairy and infant formula industry, which is distinct from many consumer staples names listed in the United States. Some US investors use such holdings to diversify geographically and by sector, complementing domestic food and beverage companies with exposure to overseas growth drivers.

At the same time, investing in Hong Kong–listed shares exposes US investors to currency considerations, differences in regulatory regimes and specific risks related to Chinese economic and policy developments. These factors can influence valuation, trading liquidity and volatility in ways that differ from US-listed consumer staples stocks.

Conclusion

China Feihe Ltd remains a prominent player in China’s infant formula market, with a business model that emphasizes branded premium products and broad distribution. Its full-year 2024 results and proposed final dividend highlight a focus on balancing shareholder returns with reinvestment in the core franchise. For US investors able to access Hong Kong–listed shares, the stock offers targeted exposure to Chinese consumer staples and demographic trends, while also carrying risks tied to local competition, regulation and macroeconomic conditions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.